Azienda Ospedaliera di Cosenza - P.O. ANNUNZIATA
- Address
- Viale della Repubblica snc, Cosenza, Italy
Azienda Ospedaliera di Cosenza - P.O. ANNUNZIATA - Hematologic Malignancies Research Center
The Azienda Ospedaliera di Cosenza - P.O. ANNUNZIATA is a distinguished clinical research institution specializing in advanced therapies for hematologic malignancies. The center demonstrates particular expertise in evaluating novel combination therapies and targeted treatment approaches for chronic leukemias and myelodysplastic syndromes, with a strong focus on precision medicine strategies tailored to patient risk profiles and molecular characteristics.
- Chronic Lymphocytic Leukemia (CLL) treatment strategies, including BCL-2 inhibitors (venetoclax), BTK inhibitors (zanubrutinib, ibrutinib), and monoclonal antibodies (obinutuzumab) with minimal residual disease monitoring
- Chronic Myeloid Leukemia (CML) management comparing tyrosine kinase inhibitors (nilotinib versus imatinib) and treatment-free remission protocols
- Myelodysplastic Syndromes (MDS) with del5q, focusing on luspatercept therapy for transfusion-dependent anemia in lenalidomide-resistant patients
- Autoimmune complications in hematologic disorders, specifically autoimmune hemolytic anemia associated with CLL/Small Lymphocytic Lymphoma
The center's research portfolio reflects a commitment to addressing unmet clinical needs in patients with high-risk disease profiles and those who have exhausted standard treatment options. Their trials emphasize measurable clinical endpoints including minimal residual disease assessment, transfusion independence, and optimal molecular response rates, positioning the institution at the forefront of personalized hematology care and innovative therapeutic development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliera di Cosenza - P.O. ANNUNZIATA
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Ibrutinib in Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or CLL-like MBL | Fondazione Gimema Franco Mandelli Onlus | Phase II | Recruiting | Nov 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allopurinol | 1 | Unknown | 2023-07-21 | 2023-07-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.